Latest News
Phathom Pharmaceuticals, Inc.
- Phathom Pharmaceuticals reports lawsuit over Voquezna exclusivity By Investing.com
- Form 8K Phathom Pharmaceuticals Inc For: 23 October By Investing.com
- Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
- Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
- Phathom Pharmaceuticals Provides Update on Litigation Filed by BDR Pharmaceuticals against FDA
- Phathom Pharmaceuticals to Host Third Quarter 2026 Financial Results Webcast on October 29
- Phathom Pharmaceuticals to Report Third Quarter 2026
- Phathom data projects vonoprazan cost-effective vs. PPIs for GERD
- Cost effectiveness and real world efficacy results revealed by Phathom Pharmaceuticals
- Phathom Pharmaceuticals Highlights New Cost-Effectiveness Data and Growing Clinical Interest in VOQUEZNA® (vonoprazan) at ACG 2026
- Phathom Pharmaceuticals Announces Initiation of
- Phathom Pharmaceuticals begins Phase 3 trial for VOQUEZNA in non-erosive GERD
Headlines from the last 30 days, linking to the original publishers. See all market news →